{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:52:38Z","timestamp":1781635958005,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Health Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epiregulin, a polypeptide involved in inflammation, cell proliferation, tumor development, and tissue remodeling pathophysiology, plays a crucial role in the etiopathogenesis of malignancies. This prospective case-control study aimed to investigate the association between epiregulin levels and various clinical and laboratory parameters in HL patients to better understand its role in the disease. This study compared newly diagnosed 56 HL patients with 56 healthy controls to assess epiregulin levels in relation to factors such as cell type, staging, extranodal involvement, \u03b22-microglobulin, lactate dehydrogenase (LDH), and C-reactive protein (CRP). Epiregulin levels were significantly elevated in HL patients (265.0 \u00b1 36.0 pg\/ml) compared to healthy controls (130.7 \u00b1 21.8 pg\/ml). While no significant differences were observed in epiregulin levels among different HL subtypes, higher levels were found in advanced stages (281.1 \u00b1 32.2 pg\/ml) compared to early stages (246.4 \u00b1 31.3 pg\/ml). Patients with splenic and extranodal involvement exhibited elevated epiregulin levels. Furthermore, a positive correlation was noted between epiregulin levels and CRP, LDH, and \u03b22-microglobulin levels in HL patients. Epiregulin levels are elevated in patients with Hodgkin lymphoma and are associated with advanced disease stage, extranodal and splenic involvement, the presence of B symptoms, and key laboratory parameters. These findings suggest that epiregulin may be related to disease burden and activity in HL. Further prospective studies are warranted to clarify its clinical relevance.<\/jats:p>","DOI":"10.1007\/s00277-026-06879-4","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:27:37Z","timestamp":1770708457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epiregulin levels and their association with prognostic factors in Hodgkin lymphoma: a case-control study"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8181-0341","authenticated-orcid":false,"given":"\u00d6zden","family":"Yildirim Akan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7787-1443","authenticated-orcid":false,"given":"\u0130smail","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9739-1607","authenticated-orcid":false,"given":"Ferda","family":"Bilgir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-5796","authenticated-orcid":false,"given":"Giray","family":"Bozkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-0624","authenticated-orcid":false,"given":"\u015eerafettin","family":"Ceylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9579-0583","authenticated-orcid":false,"given":"Oktay","family":"Bilgir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"6879_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcdb.2014.03.005","volume":"28","author":"DJ Riese 2nd","year":"2014","unstructured":"Riese DJ 2nd, Cullum RL (2014) Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol 28:49\u201356","journal-title":"Semin Cell Dev Biol"},{"issue":"23","key":"6879_CR2","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.3390\/ijms222312828","volume":"22","author":"WL Cheng","year":"2021","unstructured":"Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N et al (2021) The role of EREG\/EGFR pathway in tumor progression. Int J Mol Sci 22(23):12828","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6879_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/mc.22475","volume":"56","author":"AK Bauer","year":"2017","unstructured":"Bauer AK, Velmurugan K, Xiong KN, Alexander CM, Xiong J, Brooks R (2017) Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model. Mol Carcinog 56(1):94\u2013105","journal-title":"Mol Carcinog"},{"issue":"6","key":"6879_CR4","doi-asserted-by":"publisher","first-page":"a034819","DOI":"10.1101\/cshperspect.a034819","volume":"10","author":"JAB Bispo","year":"2020","unstructured":"Bispo JAB, Pinheiro PS, Kobetz EK (2020) Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med 10(6):a034819","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"6879_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","volume":"15","author":"J Huang","year":"2022","unstructured":"Huang J, Pang WS, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W et al (2022) Incidence, mortality, risk factors, and trends for hodgkin lymphoma: a global data analysis. J Hematol Oncol 15(1):57","journal-title":"J Hematol Oncol"},{"issue":"11","key":"6879_CR6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R, jack A, Roman E (2011) Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer 105(11):1684\u20131692","journal-title":"Br J Cancer"},{"issue":"5","key":"6879_CR7","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/cancers14051360","volume":"14","author":"V Men\u00e9ndez","year":"2022","unstructured":"Men\u00e9ndez V, Sol\u00f3rzano JL, Fern\u00e1ndez S, Montalb\u00e1n C, Garc\u00eda JF (2022) The hodgkin lymphoma immune microenvironment: turning bad news into good. Cancers (Basel) 14(5):1360","journal-title":"Cancers (Basel)"},{"issue":"2","key":"6879_CR8","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/ijms25021064","volume":"25","author":"E Rubin","year":"2024","unstructured":"Rubin E, Shan KS, Dalal S, Vu DUD, Milillo-Naraine AM, Guaqueta D et al (2024) Molecular targeting of the human epidermal growth factor Receptor-2 (HER2) genes across various cancers. Int J Mol Sci 25(2):1064","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6879_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10549-009-0536-5","volume":"122","author":"E McIntyre","year":"2010","unstructured":"McIntyre E, Blackburn E, Brown PJ, Johnson CG, Gullick WJ (2010) The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res Treat 122(1):105\u2013110","journal-title":"Breast Cancer Res Treat"},{"key":"6879_CR10","doi-asserted-by":"publisher","unstructured":"Aditi S, Bapat E, Jesser C, Lassiter K, Schwertfeger (2021) Role of NF-\u03baB and epiregulin in tumor-associated macrophages promoting therapeutic resistance to JAK Inhibition. Cancer Res 81(5 Suppl):Abstract nr PO017. https:\/\/doi.org\/10.1158\/1538-7445.TME21-PO017","DOI":"10.1158\/1538-7445.TME21-PO017"},{"issue":"1","key":"6879_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.canlet.2008.12.017","volume":"278","author":"T Kometani","year":"2009","unstructured":"Kometani T, Yoshino I, Miura N, Okazaki H, Ohba T, Takenaka T et al (2009) Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway. Cancer Lett 278(1):27\u201333","journal-title":"Cancer Lett"},{"issue":"3","key":"6879_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1158\/1940-6207","volume":"1","author":"J Zhang","year":"2008","unstructured":"Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W et al (2008) Intratumoral Epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila) 1(3):201\u2013207. https:\/\/doi.org\/10.1158\/1940-6207","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3","key":"6879_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/ijc.31892","volume":"144","author":"F Bormann","year":"2019","unstructured":"Bormann F, Stinzing S, Tierling S, Morkel M, Markelova MR, Walter J et al (2019) Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer. Int J Cancer 144(3):569\u2013581. https:\/\/doi.org\/10.1002\/ijc.31892","journal-title":"Int J Cancer"},{"issue":"45","key":"6879_CR14","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1038\/s41388-022-02476-7","volume":"41","author":"C Wang","year":"2022","unstructured":"Wang C, Long Q, Fu Q, Xu Q, Fu D, Li Y et al (2022) Targeting Epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance. Oncogene 41(45):4941\u20134959","journal-title":"Oncogene"},{"issue":"7","key":"6879_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/13543784.2016.1175435","volume":"25","author":"P Bossi","year":"2016","unstructured":"Bossi P, Alfieri S (2016) Investigational drugs for head and neck cancer. Expert Opin Investig Drugs 25(7):797\u2013810. https:\/\/doi.org\/10.1080\/13543784.2016.1175435","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"6879_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.18388\/abp.2020_6644","volume":"70","author":"X Liu","year":"2023","unstructured":"Liu X, Qin L, Li W, Fei F (2023) MicroRNA-1179 targets Epiregulin (EREG) regulates the proliferation and metastasis of human multiple myeloma cells. Acta Biochim Pol 70(2):389\u2013393. https:\/\/doi.org\/10.18388\/abp.2020_6644","journal-title":"Acta Biochim Pol"},{"issue":"54","key":"6879_CR17","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1038\/sj.onc.1209699","volume":"25","author":"K Mahtouk","year":"2006","unstructured":"Mahtouk K, Cremer FW, R\u00e8me T, Jourdan M, Baudard M, Moreaux J et al (2006) Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 25(54):7180\u20137191. https:\/\/doi.org\/10.1038\/sj.onc.1209699","journal-title":"Oncogene"},{"issue":"3","key":"6879_CR18","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s11845-024-03609-5","volume":"193","author":"I Demir","year":"2024","unstructured":"Demir I, Akan OY, Bilgir F, Yilmaz I, Bozkaya G, Bilgir O (2024) Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma. Ir J Med Sci 193(3):1201\u20131207. https:\/\/doi.org\/10.1007\/s11845-024-03609-5","journal-title":"Ir J Med Sci"},{"key":"6879_CR19","doi-asserted-by":"publisher","first-page":"1001145","DOI":"10.3389\/fimmu.2022.1001145","volume":"13","author":"ED SoRelle","year":"2022","unstructured":"SoRelle ED, Reinoso-Vizcaino NM, Horn GQ, Luftig MA (2022) Epstein-Barr virus perpetuates B cell germinal center dynamics and generation of autoimmune-associated phenotypes in vitro. Front Immunol 13:1001145. https:\/\/doi.org\/10.3389\/fimmu.2022.1001145","journal-title":"Front Immunol"},{"issue":"9","key":"6879_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3390\/pathogens10091113","volume":"10","author":"X Peng","year":"2021","unstructured":"Peng X, Zhou Y, Tao Y, Liu S (2021) Nasopharyngeal carcinoma: the role of the EGFR in Epstein-Barr virus infection. Pathogens 10(9):1113. https:\/\/doi.org\/10.3390\/pathogens10091113","journal-title":"Pathogens"},{"issue":"3","key":"6879_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.4049\/jimmunol.1400562","volume":"194","author":"M Harada","year":"2015","unstructured":"Harada M, Kamimura D, Arima Y, Kohsaka H, Nakatsuji Y, Nishida M et al (2015) Temporal expression of growth factors triggered by Epiregulin regulates inflammation development. J Immunol 194(3):1039\u20131046. https:\/\/doi.org\/10.4049\/jimmunol.1400562","journal-title":"J Immunol"},{"issue":"4","key":"6879_CR22","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1073\/pnas.96.4.1633","volume":"96","author":"DS Taylor","year":"1999","unstructured":"Taylor DS, Cheng X, Pawlowski JE, Wallace AR, Ferrer P, Molloy CJ (1999) Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci U S A 96(4):1633\u20131638. https:\/\/doi.org\/10.1073\/pnas.96.4.1633","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 6","key":"6879_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.htct.2023.11.005","volume":"46","author":"E Negreiros","year":"2024","unstructured":"Negreiros E, Bueno da Silveira TM, Fortier SC, Chiattone CS (2024) Evaluation of C-reactive protein and its prognostic relationship in patients with hodgkin\u2019s lymphoma. Hematol Transfus Cell Ther 46(Suppl 6):53\u201358. https:\/\/doi.org\/10.1016\/j.htct.2023.11.005","journal-title":"Hematol Transfus Cell Ther"},{"issue":"2","key":"6879_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/cancers16020238","volume":"16","author":"TP Vassilakopoulos","year":"2024","unstructured":"Vassilakopoulos TP, Arapaki M, Diamantopoulos PT, Liaskas A, Panitsas F, Siakantaris MP et al (2024) Prognostic impact of serum \u03b22-Microglobulin levels in hodgkin lymphoma treated with ABVD or equivalent regimens: A comprehensive analysis of 915 patients. Cancers (Basel) 16(2):238. https:\/\/doi.org\/10.3390\/cancers16020238","journal-title":"Cancers (Basel)"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06879-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06879-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06879-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:00:21Z","timestamp":1781632821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06879-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6879"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06879-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}